OSTX — OS Therapies Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1795091 ·
Last close
$0.74
Market Cap
$34.86M
52W High
$2.25
52W Low
$0.58
ADV30
636,082
Next earnings
2026-11-17
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -9,034,658 | -11,279,162 | 8,107,707 | 431,816 | 25,076,884 |
| Jun 2026 | 0 | — | -8,575,612 | -8,632,386 | 9,897,313 | 205,035 | 21,811,948 |
| Mar 2026 | 0 | — | -10,167,938 | -10,396,831 | 7,299,236 | 917,552 | 18,123,474 |
| Dec 2025 | 0 | — | -11,987,892 | -13,460,833 | 6,839,534 | 269,830 | 12,935,165 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,532,848
Investing CF
$0
Financing CF
$15,935,870
CapEx
$-466,423
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.87
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-86,215,436
Inventory
—
Receivables
$3,097,825
ST Investments
—
EBIT TTM
$-39,288,655
Pretax Income TTM
$-39,369,580
Interest Exp TTM
$80,925
Analysts
4
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,705,701 | -28,753,844 | 6,839,534 | 12,935,165 | -6,095,631 | -14,238,576 |
| Dec 2024 | 0 | -6,813,846 | -8,882,938 | 5,538,797 | 8,805,335 | -3,266,538 | -7,282,295 |
| Dec 2023 | 0 | -4,342,645 | -7,791,582 | 798,082 | 24,814,297 | -24,016,215 | -3,006,967 |
| Dec 2022 | 0 | -4,446,299 | -6,254,685 | 509,105 | 18,066,333 | -17,557,228 | -3,792,580 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$210
NetIncome TTM
$-39,369,580
OpCashFlow TTM
—
Assets (Latest)
$9,897,313
Forward EPS
$0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BMEA | Biomea Fusion, Inc. | $35.47M | $0.49 | — |
| ATHE | ALTERITY THERAPEUTICS LTD | $33.96M | $1.87 | — |
| GRCE | Grace Therapeutics, Inc. | $36.18M | $1.72 | — |
| SER | Serina Therapeutics, Inc. | $36.27M | $1.37 | — |
| CNTB | Connect Biopharma Holdings Ltd | $36.45M | $0.58 | — |
News headlines (Yahoo Finance, 1h cache)
OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company
2026-11-13 13:30 · Yahoo
OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
2026-11-10 13:15 · Yahoo
OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial
2026-11-05 13:00 · Yahoo
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
2026-10-19 12:30 · Yahoo
Rubenstein Public Relations Named Agency of Record for OS Therapies
2026-10-08 13:22 · Yahoo
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
2026-10-07 12:30 · Yahoo
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
2026-10-06 12:30 · Yahoo
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
2026-10-01 12:30 · Yahoo
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
2026-09-24 12:22 · Yahoo
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
2026-09-21 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.